Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors
- 13 November 1997
- journal article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 96 (5), 379-384
- https://doi.org/10.1111/j.1600-0447.1997.tb09933.x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Polymorphic Drug OxidationCNS Drugs, 1996
- Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in HumansBiochemistry, 1994
- Neural symptoms induced by tricyclic antidepressants: phenomenology and pathophysiologyActa Psychiatrica Scandinavica, 1992
- Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populationsEuropean Journal of Clinical Pharmacology, 1990
- Clozapine and seizuresAmerican Journal of Psychiatry, 1990
- Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in manBiochemistry, 1988
- A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquinClinical Pharmacology & Therapeutics, 1985
- Epilepsy: Psychiatric aspects and use of psychotropicsPsychosomatics, 1984
- Epileptic seizures induced by psychotropic drugsPsychological Medicine, 1977
- Acute Poisoning by Tricyclic Antidepressants: Clinical Features and Management of 100 PatientsClinical Toxicology, 1969